Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neumora Therapeutics, Inc. filings document the regulatory record for a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies that target novel mechanisms of action. The company’s 8-K reports furnish financial results, business updates, corporate presentations, and clinical-development disclosures for programs including navacaprant, NMRA-511, NMRA-898, NMRA-861, and NMRA-215.
Neumora’s SEC filings also cover proxy governance, executive compensation, board and shareholder voting matters, registered common stock, and capital-structure events. Recent disclosure areas include Regulation FD presentations, unregistered equity issuance tied to a loan conversion right, and formal exhibits that describe program plans, financing arrangements, risk statements, and public-company reporting obligations.
For Neumora Therapeutics, Inc. (NMRA), Chief Operating and Development Officer Aurora Daljit Singh reported multiple option exercises, share sales, and a new option grant. On August 20–21, 2026, Singh (and an affiliated family trust) exercised options to acquire a total of 176,060 shares of common stock at an exercise price of $0.72 per share and sold 176,060 shares in open-market transactions at weighted average prices around $1.51–$1.64 per share, including sales by the Aurora Family Trust, whose beneficiaries are immediate family members.
Separately, on August 20, 2026, Singh received a grant of 200,000 stock options with an exercise price of $1.52 per share, expiring on August 20, 2036. According to the vesting terms, 25% of these options vest on the first anniversary of August 20, 2026, and the remainder vest in equal monthly installments over the following three years.
Neumora Therapeutics, Inc. (NMRA) reported that Executive Chair of the Board Paul L. Berns received a stock option grant covering 500,000 shares of common stock at an exercise price of $1.52 per share. The option expires on August 20, 2036 and is held as a direct derivative position.
According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of August 20, 2026, and 1/48 of the total shares vest monthly thereafter so that the option becomes fully vested on the fourth anniversary of the Vesting Commencement Date.
Neumora Therapeutics, Inc. (NMRA) reported that officer Jason Duncan received a grant of stock options for 375,000 shares of common stock. The options have an exercise price of $1.52 per share and expire on August 20, 2036, with all options held as direct ownership.
According to the vesting terms, 25% of the option shares vest on August 20, 2027, the first anniversary of the Vesting Commencement Date, and the remaining shares vest in equal monthly installments over the following three years so that the grant is fully vested on the fourth anniversary.
Neumora Therapeutics, Inc. (NMRA) reported that its Chief Financial Officer and Principal Accounting Officer, Michael Lee Milligan, received a grant of stock options for 175,000 shares of common stock. The options have an exercise price of $1.52 per share and expire on August 20, 2036.
According to the vesting terms, 25% of the shares vest on the first anniversary of the August 20, 2026 vesting commencement date, and the remaining shares vest in equal monthly installments over the following three years, so that 100% of the option becomes fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. (NMRA) reported that its President & CEO, Joshua Pinto, received a grant of stock options for 500,000 shares of common stock. The options have an exercise price of $1.52 per share and expire on August 20, 2036. According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of the August 20, 2026 vesting commencement date, and the remaining shares vest in equal monthly installments over the following three years.
Neumora Therapeutics, Inc. (NMRA) reported that officer Aurora Daljit Singh filed a notice of proposed sale of 41,608 shares of common stock of Neumora Therapeutics, Inc. The shares are tied to the exercise of employee stock options and are expected to be disposed of on 08/21/2026 through a broker assisted cashless sale on NASDAQ via Merrill Lynch.
The filing also lists prior sales of Neumora common stock by Aurora Daljit Singh during the past three months on four dates in August 2026, each with specified share counts and total sale prices.
Neumora Therapeutics, Inc. (NMRA) received a Rule 144 notice from officer Daljit Singh Aurora covering a proposed sale of up to 134,452 shares of common stock. The shares are to be sold through Merrill Lynch on NASDAQ, in connection with the exercise of employee stock options, using a broker assisted cashless sale, with a stated aggregate market value of $203,583.59. As context, the notice lists 187,895,912 shares of Neumora common stock outstanding and discloses additional sales of Neumora common stock by the same person during the prior three months.
Neumora Therapeutics, Inc. (NMRA) reported insider transactions by Chief Operating and Development Officer Aurora Daljit Singh over August 17–19, 2026. Singh exercised stock options at an exercise price of $0.72 per share for a total of 243,753 shares of common stock and reported 277,773 shares sold in open-market transactions at weighted average prices within ranges running from about $1.46 to $1.70 per share. Some transactions involved shares held indirectly through the Aurora Family Trust, whose beneficiaries are members of Singh’s immediate family.
Neumora Therapeutics, Inc. (NMRA) received a Rule 144 notice from officer Daljit Singh Aurora covering a planned sale of 61,918 shares of common stock on 08/19/2026, to be effected via a broker assisted cashless sale following the exercise of employee stock options. The notice also lists prior sales in the last three months totaling 215,855 shares of common stock for an aggregate of $329,757.06.
Neumora Therapeutics, Inc. (NMRA) insider Aurora Daljit Singh filed a notice to sell common stock under Rule 144. The filing covers a proposed sale of 69,149 shares of common stock through Merrill Lynch in a broker assisted cashless sale, with an aggregate market value of $109,621.88, based on 187,895,912 shares outstanding, with an approximate sale date of 08/18/2026. The shares are to be sold in connection with the exercise of employee stock options, and Singh previously sold 146,706 shares on 08/17/2026 for $220,135.18.